Analyst consensus rating
Recursion Pharmaceuticals Analyst Rating: Buy
Direct answer
Recursion Pharmaceuticals's consensus rating is Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.32.
Forecast evidence checked November 12, 2026.
Get free Recursion Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.59
- Average price target
- $7.32
- High price target
- $10.00
- Low price target
- $4.00
- Low target gap
- +11.4%
- Target upside
- +103.8%
- High target gap
- +178.6%
- Target range width
- 167.1%
- Consensus rating
- Buy
- Analysts
- 6
- Evidence date
- November 12, 2026
- Valid through
- November 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Recursion Pharmaceuticals?
Recursion Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $7.32.
How far are Recursion Pharmaceuticals's low and high targets from the recorded price?
The low target implies +11.4%, while the high target implies +178.6%.
How many analysts are included in Recursion Pharmaceuticals's consensus?
The verified consensus includes 6 analysts.
How is Recursion Pharmaceuticals's target upside or downside calculated?
The average target of $7.32 is divided by the recorded price of $3.59, then one is subtracted to produce +103.8%. This does not guarantee a future return.
When was Recursion Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-11-12. The dataset is valid through 2026-11-19.